推荐产品
方案
≥98% (HPLC)
表单
powder
溶解性
methylene chloride: 50 mg/mL
运输
dry ice
储存温度
−20°C
SMILES字符串
CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c3ncn(C(C)C)c3n1
InChI
1S/C19H25ClN6O/c1-11(2)15(9-27)23-19-24-17(22-14-7-5-6-13(20)8-14)16-18(25-19)26(10-21-16)12(3)4/h5-8,10-12,15,27H,9H2,1-4H3,(H2,22,23,24,25)/t15-/m0/s1
InChI key
PMXCMJLOPOFPBT-HNNXBMFYSA-N
生化/生理作用
Purvalanol A is a potent, cell-permeable cyclin-dependent protein kinase (cdk) inhibitor.
Purvalanol A is found to inhibit ABCG2 (ATP-binding cassette G2) transporter in vitro. It is also known to attenuate cellular Src kinase action and induce cell cycle arrest at the G2 to M phase transition.
特点和优势
This compound is featured on the CDKs page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
个人防护装备
Eyeshields, Gloves, type N95 (US)
法规信息
新产品
Cell death & disease, 10(6), 385-385 (2019-05-18)
SE translocation (SET), an inhibitor of protein phosphatase 2A (PP2A), plays important roles in mitosis and possesses oncogenic activity in several types of cancer. However, little is known regarding its regulation. Here we reveal a novel phosphorylation site of SET
Anthraquinones?Advances in Research and Application: 2012 Edition, 4-4 (2012)
PloS one, 11(1), e0146227-e0146227 (2016-01-08)
Adaptive immune responses are complex dynamic processes whereby B and T cells undergo division and differentiation triggered by pathogenic stimuli. Deregulation of the response can lead to severe consequences for the host organism ranging from immune deficiencies to autoimmunity. Tracking
Cancer letters, 383(2), 295-308 (2016-10-25)
5-fluorouracil (5-FU)-based chemotherapy is the main chemotherapeutic approach for colorectal cancer (CRC) treatment. Because chemoresistance occurs frequently and significantly limits CRC therapies, a novel agent is needed. Pseudolaric acid B (PAB), a small molecule derived from the Chinese medicinal herb
Nature communications, 8(1), 1995-1995 (2017-12-10)
Adaptive therapy (AT) aims to control tumour burden by maintaining therapy-sensitive cells to exploit their competition with resistant cells. This relies on the assumption that resistant cells have impaired cellular fitness. Here, using a model of resistance to a pharmacological
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门